Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1990 participants.
Also called NCT04707261
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,990 participants
- Registry
-
NCT04707261
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04707261. Randomized; double masking; primary purpose treatment. Start 2021-08-06 (actual); primary completion 2025-05-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
- Acronym
- ADIDAS
- Condition
- Anemia
- Condition
- Heart Failure
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Xiangtan Central Hospital
- Collaborator
- Second Xiangya Hospital of Central South University
- Collaborator
- ZhuZhou Central Hospital
Record details
- Record id
cardio:ct-nct04707261- Content hash
bfd91ac6426b229a648b118108ebd3006900a211f6f3cfb890709ca6e343e693